Enabling life changing cell and gene therapy.

Proprietary Subzero Unfrozen (SU) cell storage for optimal cell viability and function.

Learn More

Our story begins in the Arctic.

CryoStasis’ revolutionary approach to preserving biological material traces its roots to the Canadian Arctic. Born of biochemist Olga Kukal’s fascination with the winter survival strategies of insects, our technology rejects a commonly held belief – that in order to preserve life, we must freeze it.

Introducing Woolii™ SU – The Platform for Subzero Unfrozen Cell Preservation

Our novel cold chain management process using a combination of media, temperature and pressure to preserve biological material indefinitely.

Media

One formulation for short or long-term storage that leverages cold shock inhibitors and membrane protectants to prevent cryoinjury to cells.

Temperature Systems

Our devices and shipping solutions ensure viability and provide the flexibility to easily integrate into manufacturing and logistics.

Pressure Systems

Pressurization lowers the freezing point, and along with it, cell metabolism, thereby enabling long-term storage.

Learn More

The time to invest in your production capabilities is now.

FDA approved Cell & Gene Therapies

(per FDA’s Office of Tissue and Advanced Therapies, June 2024)

Approved therapies by 2026

(per Tufts University’s Center for Biomedical System Design analysis, May 2024)

21%

Projected annual growth of therapeutics and enabling technologies

Optimal viability, function and potency.

CryoStasis’ clinically proven technology makes it possible to go from production line to bedside with one formulation. Our serum-free, DMSO-free, chemically defined media and subzero unfrozen platform easily integrate into any manufacturing process.

Learn More

Latest Insights

CryoStasis Participating in the 2025 J.P. Morgan Biotech Showcase

CryoStasis will be presenting business updates and scientific results from our recently launched Early Access Program and select Investigator Initiated Studies.

Learn More
Biopreservation Benchmarking Results from OHRI’s Biotherapeutics Manufacturing Center

Highlights from the ongoing collaboration between OHRI's BMC and CryoStasis presented at the 2024 Till & McCullouch Meeting

Learn More
Kidney Transplant Results presented at the American Society of Nephrology Annual Meeting in Philadelphia

CryoStasis & UHN deliver compelling kidney transplant results for subzero unfrozen preservation technology

Learn More
CryoStasis closes $8M financing round

Exciting news in support of the CryoStasis mission

Learn More

Our Team

Aaron Del Duca

CEO

Aaron Del Duca is a product and business unit leader with over 20 years of experience in medical devices, molecular diagnostics, and SaaS. Aaron excels at identifying market opportunities, developing innovative solutions, and forging strategic partnerships with industry leaders. With a background in molecular biology and a passion for building from zero-to-one, he has consistently driven transformative growth in public and private companies, with a focus on improving predictive and preventive healthcare.
Jeremy Rutke

Chief Financial Officer

Jeremy is an experienced executive with over 15 years of leadership in finance, accounting, and compliance. With his time in the investment finance, real estate and investment management industries, he has a strong functional ability to lead complex initiatives and help businesses achieve their strategic goals. Jeremy completed the accounting program at the Sprott School of Business and worked in Deloitte’s audit practise, where he obtained his CPA, CA designation.
Jan Kaminski

Executive Chairman

Jan brings decades of global growth and leadership experience to the CryoStasis team, including 15 years as President of Colonnade Investments. He’s guided venture-backed start-ups to successful M&As and held several advisory and board positions among a number of corporations and not-for-profits. His experience spans industries including agriculture, enterprise management, medical device technologies and more.
Thomas Allen

Co-Founder, Senior Scientific Advisor

Tom is a physical chemist with an extensive academic and professional background. While doing a postdoctoral fellowship at Ohio State, Tom met his wife, Dr. Olga Kukal. Over the course of three decades, the two founded three biotechnical companies to actualize the transformative potential of Olga’s research. As CSO, Tom honours Olga’s memory by continuing to advance the research she began more than 40 years ago and that, together, they distilled into a life-changing technology.